Please select the option that best describes you:

Would you recommend complement testing in a kidney transplant recipient with chronic antibody-mediated rejection and biopsy-proven thrombotic microangiopathy to determine the need for eculizumab?  



Answer from: at Community Practice
Comments
at Washington University in St. Louis
That's very helpful, thank you Dr. @Lee.
at University Of Alabama Birmingham Nephrology
I agree with Dr. @Lee that tocilizumab holds promi...
at Washington University in St. Louis
Got it Dr. @Ong. Thank you!
Sign in or Register to read more